A novel PPAR agonist with predominant PPARα and moderate PPARγ activity with EC50 of 0.65 pM and 3 nM respectively; has been developed for the treatment of dyslipidaemia and has favourable effects on glycaemic parameters in type 2 diabetes mellitus.
Diabetes
Approved
Physicochemical Properties
M.Wt
450.71
Formula
C25H28NO4S.1/2Mg
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
Benzenepropanoic acid, α-ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]-,magnesium salt (2:1),(αS)-,
References
1. Agrawal R. Curr Drug Targets. 2014 Feb;15(2):151-5.
2. Jani RH, et al. Clin Drug Investig. 2013 Nov;33(11):809-16.
3. Jain MR, et al. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.
